HOB Biotech Group Corp. Ltd. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 7.30% and Operating profit at -28.69% over the last 5 years

The company has declared Negative results for the last 3 consecutive quarters

With ROE of 3.56%, it has a very expensive valuation with a 2.28 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 1,856 Million (Mid Cap)

P/E

64.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.04

Return on Equity

3.56%

Price to Book

2.28

Revenue and Profits:

Net Sales:

112 Million

(Quarterly Results - Jun 2025)

Net Profit:

11 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

8.15%

6 Months

66.48%

1 Year

77.8%

2 Years

400.14%

3 Years

414.1%

4 Years

206.56%

5 Years

0.0%

HOB Biotech Group Corp. Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

HOB Biotech Soars 5.33%, Hits Intraday High of CNY 163.00

HOB Biotech Group Corp. saw a significant rise on October 30, 2025, outperforming the Shanghai Composite. Over the past year, the company has achieved remarkable growth, despite facing challenges such as declining net sales and negative quarterly results, raising concerns about its long-term sustainability in the biotechnology sector.

HOB Biotech Stock Hits Day High with Strong 5.3% Intraday Surge

HOB Biotech Group Corp. has seen significant stock gains recently, outperforming the China Shanghai Composite. Over the past month, the stock has increased by 28.19%, with a remarkable 527.92% rise over the past year. However, the company faces challenges, including declining net sales and negative quarterly results.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

7.30%

EBIT Growth (5y)

-28.69%

EBIT to Interest (avg)

32.88

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

0.04

Sales to Capital Employed (avg)

0.43

Tax Ratio

11.66%

Dividend Payout Ratio

50.85%

Pledged Shares

Institutional Holding

ROCE (avg)

11.39%

ROE (avg)

6.28%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.28

EV to EBIT

89.62

EV to EBITDA

27.83

EV to Capital Employed

2.28

EV to Sales

4.85

PEG Ratio

Dividend Yield

ROCE (Latest)

2.54%

ROE (Latest)

3.56%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

Bullish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -3.45% vs 6.91% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -35.19% vs 1.25% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "112.00",
          "val2": "116.00",
          "chgp": "-3.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.00",
          "val2": "33.00",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.70",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "10.50",
          "val2": "16.20",
          "chgp": "-35.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "173.80%",
          "chgp": "-17.38%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1.57% vs 22.98% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -22.20% vs 13.43% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "395.70",
          "val2": "389.60",
          "chgp": "1.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "98.20",
          "val2": "100.60",
          "chgp": "-2.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.00",
          "val2": "2.80",
          "chgp": "7.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.10",
          "val2": "0.40",
          "chgp": "-375.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "36.80",
          "val2": "47.30",
          "chgp": "-22.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "111.20%",
          "val2": "136.80%",
          "chgp": "-2.56%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

112.00

116.00

-3.45%

Operating Profit (PBDIT) excl Other Income

0.00

33.00

-100.00%

Interest

0.00

0.70

-100.00%

Exceptional Items

0.00

Consolidate Net Profit

10.50

16.20

-35.19%

Operating Profit Margin (Excl OI)

0.00%

173.80%

-17.38%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is -3.45% vs 6.91% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -35.19% vs 1.25% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

395.70

389.60

1.57%

Operating Profit (PBDIT) excl Other Income

98.20

100.60

-2.39%

Interest

3.00

2.80

7.14%

Exceptional Items

-1.10

0.40

-375.00%

Consolidate Net Profit

36.80

47.30

-22.20%

Operating Profit Margin (Excl OI)

111.20%

136.80%

-2.56%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 1.57% vs 22.98% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -22.20% vs 13.43% in Dec 2023

All Annual Results

Company CV

About HOB Biotech Group Corp. Ltd.

HOB Biotech Group Corp. Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

HOB Biotech Group Corp. Ltd.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 7.30% and Operating profit at -28.69% over the last 5 years

The company has declared Negative results for the last 3 consecutive quarters

With ROE of 3.56%, it has a very expensive valuation with a 2.28 Price to Book Value

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

HOB Biotech Soars 5.33%, Hits Intraday High of CNY 163.00

HOB Biotech Stock Hits Day High with Strong 5.3% Intraday Surge

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About HOB Biotech Group Corp. Ltd.

Company Coordinates